Breaking News
Investing Pro 0
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started

Fate Therapeutics collapses 55% after terminating Janssen deal, earns several downgrades

Stock Markets Jan 06, 2023 08:57
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
JNJ
+0.82%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
FATE
+2.66%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Senad Karaahmetovic 

Shares of Fate Therapeutics (NASDAQ:FATE) are down more than 56% in pre-market after the company said it has declined a proposal from Janssen Biotech, which is owned by Johnson & Johnson (NYSE:JNJ), for the continuation of the collaboration and option agreement between the parties.

As a result, the agreement has been terminated and the FT596 product candidate is discontinued. Instead, the company plans to focus on its CD19-targeted CAR NK cell program.

"We are disappointed that we were not able to align with Janssen on their proposal for continuation of our collaboration, where two product candidates targeting high-value, clinically-validated hematology antigens were set to enter clinical development in 2023," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Fate added that it ended the fourth quarter with about $475 million in cash and is expected to have sufficient financial resources through the end of 2025.

The massive selloff in FATE stock has been accelerated by at least 8 downgrades following the announcement. Truist analysts downgraded to Hold with a $7 per share price target (down from the prior $46).

"In the near-term we remain on the sidelines as we await greater clarity on strategy, FDA feedback on how to move forward and timelines for data readouts from next-gen assets… In the longer-term, we see focus on nextgen as a smart move, and believe company has been telegraphing that for a while," the analysts wrote in a note.

BMO analysts cut the rating to Market Perform from Outperform as the prior buy thesis on the stock has now been challenged.

"While FATE's actions will help extend cash runway through 2025, we see limited opportunities for value generation near and medium-term and lack sufficient data pointing to competitive profiles from ongoing programs (ASH takeaways). As a result, we're removing discontinued programs from our model and downgrading to Market Perform," they said.

As of 08:28 GMT (13:28 GMT), FATE stock trades 56.36% lower.

Fate Therapeutics collapses 55% after terminating Janssen deal, earns several downgrades
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email